Unlike many conventional small-molecule medicines that can be chemically synthesized, biotherapeutics are often produced through biological systems such as bacteria, yeast or mammalian cell cultures. The World Health Organization describes biological therapeutics as a broad group that includes monoclonal antibodies, vaccines, growth factors, immune modulators and other biological medicines.

The field has become increasingly important in areas such as cancer, autoimmune disorders, diabetes, rare diseases, infectious diseases and genetic conditions.

Modern biotherapeutics research also increasingly involves recombinant DNA technology, antibody engineering, cell and gene therapies, RNA technologies, computational biology and advanced biomanufacturing.

What Is a Biotherapeutics Company?

A biotherapeutics company is an organization that researches, develops or manufactures medicines derived from biological systems.

Its work may involve:

• Proteins
• Antibodies
• Recombinant molecules
• Hormones
• Enzymes
• Vaccines
• Cell-based therapies
• Gene-based therapies
• RNA-based therapeutics
• Immune-modulating medicines
• Other biological molecules

WHO notes that modern biotherapeutic development can use genetically engineered bacteria, yeast, fungi, cells, plants and other biological systems to produce medicinal products.

A company may specialize in one technology platform or combine several platforms across its research pipeline.

What Are Biotherapeutics?

Biotherapeutics are medicines derived from biological or living sources.

They can include:

• Monoclonal antibodies
• Recombinant proteins
• Growth factors
• Hormones
• Cytokines
• Enzymes
• Vaccines
• Cell therapies
• Gene therapies
• Certain blood-derived products

For example, insulin, interferons and monoclonal antibodies are among the biological therapeutics used in modern medicine.

Their biological origin makes them fundamentally different from many traditional chemical medicines.

Biotherapeutics vs Small-Molecule Medicines

The difference can be summarized as follows:

Biotherapeutics can be more difficult to characterize because their properties are closely connected with biological production processes. WHO emphasizes that biological medicines require specialized quality, safety and efficacy controls.

Major Types of Biotherapeutics Companies

Monoclonal Antibody Companies

Monoclonal antibodies, often abbreviated as mAbs, are engineered proteins designed to recognize specific biological targets.

They are widely studied and used in areas such as:

• Cancer
• Autoimmune diseases
• Inflammatory disorders
• Infectious diseases
• Immunological conditions

WHO's clinical research landscape identified more than 2,000 monoclonal-antibody clinical trials during the 2014–2023 period, demonstrating the importance of this therapeutic class.

Recombinant Protein Companies

These companies develop proteins produced using genetically engineered biological systems.

Examples can include:

• Hormones
• Growth factors
• Enzymes
• Blood-related proteins
• Therapeutic proteins

Recombinant DNA technology made it possible to produce large quantities of highly purified and characterized biological proteins.

Cell Therapy Companies

Cell therapy companies investigate the use of living cells as therapeutic agents.

Research can include:

• Immune cells
• Stem-cell-based approaches
• Genetically modified cells
• Regenerative applications
• Cancer cell therapies

Gene Therapy Companies

Gene therapy companies focus on approaches that introduce, modify or regulate genetic material to address disease mechanisms.

Research areas can include:

• Genetic disorders
• Rare diseases
• Cancer
• Inherited conditions
• Genome editing

RNA Therapeutics Companies

RNA-based technologies represent another growing area of biotechnology research.

They can involve:

• Messenger RNA
• Small interfering RNA
• Antisense RNA
• RNA vaccines
• RNA editing
• Gene regulation

Vaccine Biotechnology Companies

These organizations research biological approaches for preventing infectious diseases.

Platforms may include:

• Recombinant vaccines
• Protein-based vaccines
• Viral-vector approaches
• RNA-based vaccines
• Other biological vaccine technologies

How Biotherapeutics Companies Conduct Research

Biotherapeutic development normally progresses through several stages.

1. Biological Research

Scientists first investigate disease mechanisms, biological pathways and potential therapeutic targets.

2. Target Identification

Researchers identify a molecule, receptor, protein, gene or cellular process that may influence the disease.

3. Candidate Discovery

Potential therapeutic molecules, antibodies, proteins, cells or genetic approaches are investigated.

4. Laboratory Evaluation

Candidates undergo laboratory testing to understand:

• Biological activity
• Selectivity
• Stability
• Mechanism
• Potential safety concerns

5. Preclinical Development

Promising candidates undergo further studies before human testing.

6. Clinical Research

Eligible candidates progress through regulated clinical studies involving human participants.

7. Manufacturing Development

The production process is optimized to achieve consistent quality.

8. Regulatory Evaluation

Regulatory authorities assess scientific and clinical evidence before authorization.

9. Ongoing Monitoring

Biological medicines may require continued safety and quality monitoring after authorization.

The precise pathway varies depending on the therapeutic category and jurisdiction.

Core Technologies Used by Biotherapeutics Companies

Recombinant DNA Technology

Recombinant DNA technology allows researchers to introduce specific genetic sequences into biological systems.

Engineered cells can then produce therapeutic proteins.

This technology transformed the production of many modern biological medicines.

Cell Culture

Cells are grown under controlled laboratory conditions to produce or investigate biological materials.

Cell culture can support:

• Protein production
• Antibody production
• Vaccine research
• Cell therapy research
• Disease modeling

Protein Engineering

Protein engineering can modify therapeutic proteins to investigate characteristics such as:

• Stability
• Binding
• Activity
• Half-life
• Specificity

Antibody Engineering

Researchers can modify antibody structures to improve their biological characteristics or target specific molecules.

Genome Editing

Genome-editing technologies can modify genetic material within cells.

These technologies are being investigated across:

• Rare diseases
• Cancer
• Genetic disorders
• Cell therapy
• Biological research

Bioinformatics

Biotherapeutics research generates large amounts of biological data.

Bioinformatics can help researchers analyze:

• Genomic information
• Protein sequences
• Molecular interactions
• Clinical data
• Biomarkers
• Biological pathways

Artificial Intelligence

AI is increasingly being investigated for biological discovery and drug-development workflows.

Potential applications include:

• Protein structure prediction
• Molecular analysis
• Biomarker discovery
• Candidate prioritization
• Clinical data analysis
• Research automation

However, computational predictions still require appropriate experimental and clinical validation.

Role of Biomanufacturing

Manufacturing is one of the defining components of biotherapeutics development.

A biological medicine may be produced using:

• Bacterial cells
• Yeast
• Mammalian cells
• Insect cells
• Plant systems
• Other engineered biological platforms

The manufacturing process can influence the final characteristics of a biological product.

This is one reason biological medicines require extensive testing and quality controls at different stages of production. WHO emphasizes batch consistency, quality, safety and efficacy as important considerations for biological therapeutics.

From Laboratory to Large-Scale Production

Scaling biological production is significantly more complicated than simply increasing the size of a laboratory container.

Companies need to consider:

• Cell growth
• Nutrient conditions
• Temperature
• Oxygen
• pH
• Contamination control
• Purification
• Filtration
• Stability
• Storage
• Quality testing

Bioreactors

Bioreactors provide controlled environments for biological production.

Depending on the process, they can regulate:

• Temperature
• pH
• Oxygen
• Agitation
• Nutrient supply

Purification

After biological production, the desired molecule needs to be separated from other biological components.

Purification may involve multiple specialized steps.

Quality Control

Analytical testing helps evaluate characteristics such as:

• Identity
• Purity
• Potency
• Stability
• Biological activity
• Consistency

Biotherapeutics and Biosimilars

Biosimilars are biological products designed to be highly similar to an already authorized reference biological medicine.

They are not identical copies in the same way that conventional generic chemical medicines can be.

This distinction exists because biological medicines are complex molecules produced through biological systems.

WHO explains that conventional generic concepts based on chemical equivalence are not directly applicable to complex biotherapeutics.

Biosimilar development therefore involves a specialized comparison of analytical, functional and clinical evidence.

Why Biosimilars Matter

Biosimilars can broaden the range of biological medicines available within healthcare systems.

They are particularly relevant as intellectual-property and regulatory protections for earlier biological medicines expire.

WHO identifies biosimilars as an important component of efforts to improve access to biological medicines.

Major Therapeutic Applications

Cancer

Biotherapeutics have transformed many areas of oncology.

Applications include:

• Monoclonal antibodies
• Immune-modulating therapies
• Cell therapies
• Antibody-based approaches
• Gene-based research

Monoclonal antibodies remain particularly important in cancer research and clinical development.

Autoimmune Diseases

Biological medicines can target specific components of the immune system.

Research and applications include conditions such as:

• Rheumatoid arthritis
• Inflammatory bowel disease
• Lupus
• Other immune-mediated disorders

Diabetes

Biological technologies have played a major role in the development and production of therapeutic insulin.

Rare Diseases

Biotherapeutics can be particularly valuable for rare genetic and biological disorders where conventional approaches may not adequately address the underlying disease mechanism.

Infectious Diseases

Vaccines, antibodies and other biological approaches contribute to infectious-disease prevention and treatment.

Blood Disorders

Biological technologies have enabled the development of recombinant and plasma-derived therapeutic products.

Research Areas Within a Biotherapeutics Company

A large organization can contain several specialized research groups.

Discovery Research

Focuses on identifying promising biological targets and therapeutic candidates.

Translational Research

Connects laboratory discoveries with potential clinical applications.

Clinical Research

Evaluates therapeutic candidates in human studies under regulated protocols.

Biomarker Research

Investigates biological indicators that may help identify disease characteristics or treatment responses.

Process Development

Works on scalable and reproducible biological manufacturing processes.

Analytical Development

Creates methods for measuring product characteristics and quality.

Regulatory Research

Prepares scientific and technical information required for regulatory interactions.

Regulatory and Quality Considerations

Biotherapeutics require specialized regulatory oversight because of their biological complexity.

Important areas include:

• Product identity
• Purity
• Potency
• Safety
• Stability
• Manufacturing consistency
• Clinical evidence
• Biological activity
• Contamination control

WHO maintains international standards and guidance related to the quality, safety and efficacy of biological medicines.

Regulatory requirements differ by country, therapeutic category and development stage.

Challenges Facing Biotherapeutics Companies

Biological Complexity

Biological molecules can have complex structures that are difficult to fully characterize.

Manufacturing Consistency

Small changes in biological manufacturing processes can potentially affect product characteristics.

Clinical Uncertainty

A promising laboratory candidate may not demonstrate sufficient efficacy or safety in human studies.

Delivery

Some biological molecules may have difficulty reaching the appropriate tissue or cellular target.

Stability

Certain biological medicines can be sensitive to temperature, formulation and storage conditions.

Immunogenicity

Some biological proteins can trigger unwanted immune responses.

Regulatory Complexity

Biological medicines require extensive scientific and regulatory documentation.

Research and Development Productivity

Biotherapeutics research is scientifically demanding, and organizations must continuously improve the ability to identify promising candidates and move them through development.

A 2026 Nature Reviews Drug Discovery report highlights efforts by biopharmaceutical companies in Asia and emerging markets to improve R&D productivity and increase investment in innovative and differentiated assets.

Recent Industry Insights

Growing Role of Biological Medicines

Biological medicines have become an important part of modern healthcare, with applications spanning cancer, autoimmune disease, diabetes, infectious disease and other conditions.

Monoclonal Antibodies Remain Important

Monoclonal antibodies continue to represent one of the major biotherapeutic classes, with extensive clinical research across multiple therapeutic areas.

Expansion of Advanced Therapies

Cell and gene therapies are expanding the definition of what can be considered a biological therapeutic.

These approaches move beyond traditional proteins and antibodies toward living cells and genetic technologies.

AI and Computational Biology

AI is increasingly becoming part of biological research, potentially supporting target identification, molecular analysis and candidate prioritization.

Manufacturing Innovation

Advanced biomanufacturing remains important as companies attempt to improve production consistency, scalability and biological product quality.

Biosimilar Development

Biosimilars continue to receive attention as healthcare systems look for ways to expand access to biological medicines.

Biotherapeutics Company vs Biotechnology Company

The terms overlap, but they are not always identical.

A biotherapeutics company can therefore be considered a specialized type of biotechnology organization focused primarily on biological medicines.

Biotherapeutics Company vs Traditional Pharmaceutical Company

The boundary between these categories has become increasingly blurred.

Traditional pharmaceutical companies may develop:

• Small-molecule medicines
• Biological medicines
• Vaccines
• Cell therapies
• Gene therapies

Biotherapeutics-focused companies generally place greater emphasis on biological platforms.

Modern pharmaceutical research increasingly combines both chemical and biological approaches.

Future of Biotherapeutics

The future of biotherapeutics is likely to involve increasing convergence between biology, engineering, computing and medicine.

Important areas include:

• Next-generation antibodies
• Bispecific antibodies
• Cell therapies
• Gene editing
• RNA therapeutics
• Protein engineering
• AI-assisted discovery
• Precision medicine
• Advanced vaccine technologies
• Targeted biological delivery
• Automated laboratories
• Continuous biomanufacturing

The development of new biological platforms could allow researchers to address diseases at increasingly specific molecular and cellular levels.

At the same time, manufacturing, safety, regulatory oversight and equitable access will remain important parts of the field.

How to Research a Biotherapeutics Company

When evaluating a biotherapeutics company for educational or industry research, consider:

Research Focus

What biological problem does the organization investigate?

Technology Platform

Does it focus on antibodies, proteins, cells, genes, RNA or another biological platform?

Development Stage

Determine whether its candidates are:

• Early research
• Preclinical
• Clinical
• Regulatory review
• Authorized

Scientific Evidence

Look for peer-reviewed publications, clinical-trial information and credible scientific evidence.

Manufacturing Platform

Understand how the organization produces and evaluates its biological candidates.

Regulatory Status

Check the relevant national regulatory authority for current information.

Research Pipeline

Review the therapeutic areas and development stages represented in the organization's pipeline.

WHO recommends using sources such as clinical-trial registries, company and university information and other specialized databases when conducting health-product landscape research.

Frequently Asked Questions

What does a biotherapeutics company do?

A biotherapeutics company researches, develops or manufactures medicines derived from biological systems. These can include proteins, antibodies, vaccines, cells and gene-based therapies.

What are examples of biotherapeutics?

Examples include monoclonal antibodies, recombinant proteins, insulin, certain vaccines, growth factors, interferons and some cell and gene therapies.

Are biotherapeutics the same as biologic medicines?

The terms are closely related and can overlap. Biotherapeutics generally refers to therapeutic products derived from biological sources, while “biologics” is a broader regulatory and scientific category whose exact scope can vary by jurisdiction.

What technologies are used by biotherapeutics companies?

Common technologies include recombinant DNA, cell culture, protein engineering, antibody engineering, genome editing, RNA technologies, bioinformatics and biomanufacturing.

What is the difference between a biosimilar and a generic?

A generic is generally a chemically synthesized medicine demonstrated to be equivalent to its reference medicine. A biosimilar is a biological product shown to be highly similar to an existing reference biological medicine, using specialized analytical and clinical evidence.

Conclusion

Biotherapeutics companies represent one of the most important intersections of modern biotechnology and medicine. Their research involves biological molecules, engineered cells, genetic technologies and increasingly sophisticated computational tools.

From monoclonal antibodies and recombinant proteins to cell and gene therapies, the field continues to expand the range of biological approaches available for understanding and addressing disease.

The industry's future will depend not only on scientific discovery but also on reliable manufacturing, rigorous clinical evaluation, regulatory standards, research productivity and broader access to biological medicines.

As biotechnology continues to advance, biotherapeutics companies are likely to remain central to the development of increasingly targeted and biologically sophisticated medical approaches.

Disclaimer

This article is provided for general educational and informational purposes only. It is not medical, scientific, regulatory, legal or professional advice and does not endorse any particular company, medicine, therapy or biotechnology platform. Biological medicines, clinical research and regulatory requirements can change over time. Readers should consult authoritative regulatory agencies, peer-reviewed scientific literature and qualified healthcare or scientific professionals for decisions involving medicines, clinical trials, biotechnology research or patient care.